Biblio

Found 24 results
Author Keyword [ Title(Desc)] Type Year
Filters: Author is Amit M Oza  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
T. J. Perren, Swart, A. Marie, Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G. B., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., du Bois, A., Sehouli, J., Kimmig, R., Stähle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M. R., Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M. K. B., and Oza, A. M., A phase 3 trial of bevacizumab in ovarian cancer., N Engl J Med, vol. 365, no. 26, p. 2496, 2011.
P. Hoskins, Eisenhauer, E., Vergote, I. B., Dubuc-Lissoir, J., Fisher, B., Grimshaw, R., Oza, A. M., Plante, M., Stuart, G. C. E., and Vermorken, J. B., Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study., J Clin Oncol, vol. 18, no. 24, pp. 4038-44, 2000.
H. Mackay, Brady, M. F., Oza, A. M., Reuss, A., Pujade-Lauraine, E., Swart, A. Marie, Siddiqui, N. Ahmad, Colombo, N., Bookman, M. A., Pfisterer, J., du Bois, A., and InterGroup, G. Cancer, Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer, Int J Gynecol Cancer, vol. 20, pp. 945-52, 2010.
J. A. Green, F, D., Coens, C., S, L., Vergote, I. B., Eisenhauer, E., Bacon, M., W, C., van der Burg, M. E. L., and Oza, A. M., Prognostic value of clinical and molecular markers in advanced ovarian cancer: importance of residual disease. Translational study using tumor specimens from EORTC 55931/NCIC OV10 phase III randomized clinical trial. , Proc Am Soc Clin Oncol , vol. 23, no. 16S Part 1, 2005.
S
S. A. Welch, Hirte, H., Elit, L., Schilder, R. J., Wang, L., Macalpine, K., Wright, J. J., and Oza, A. M., Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium, Int J Gynecol Cancer, vol. 20, pp. 787-93, 2010.
A. M. Oza, Cook, A. D., Pfisterer, J., Embleton, A. C., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G. B., Carey, M. S., Beale, P., Cervantes, A., Park-Simon, T. - W., Rustin, G. J. S., Joly, F., Mirza, M. R., Plante, M., Quinn, M., Poveda, A. M., Jayson, G. C., Stark, D., Swart, A. Marie, Farrelly, L., Kaplan, R. S., Parmar, M. K. B., and Perren, T. J., Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial., Lancet Oncol, vol. 16, no. 8, p. 936, 2015.
D. Stark, Nankivell, M., Pujade-Lauraine, E., Kristensen, G. B., Elit, L., Stockler, M., Hilpert, F., Cervantes, A., Brown, J., Lanceley, A., Velikova, G., Sabate, E., Pfisterer, J., Carey, M. S., Beale, P., Qian, W., Swart, A. Marie, Oza, A. M., and Perren, T. J., Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial., Lancet Oncol, vol. 14, no. 3, p. 243, 2013.
B. You, Colomban, O., Heywood, M., Lee, C., Davy, M., Reed, N. Simon, Pignata, S., Varsellona, N., Emons, G., Rehman, K., Steffensen, K. Dahl, Reinthaller, A., Pujade-Lauraine, E., and Oza, A. M., The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study)., Gynecol Oncol, vol. 130, no. 2, p. 294, 2013.
M. Leonard Friedlander, Stockler, M., O'Connell, R., Voysey, M., Oza, A. M., Gillies, K., Donovan, H., Martyn, J., Sjoquist, K. Marie, Butow, P., King, M. Trudy, and Group, S. Benefit St, Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the Gynecologic Cancer Intergroup symptom benefit study, Int J Gynecol Cancer, vol. 24, pp. 857-64, 2014.